Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02040142 · OUTCOME

Overall Survival (OS)

HIPEC for Peritoneal Carcinomatosis · Source last updated 2024-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Up to 5 years

What was measured

Overall survival will be calculated from the time of surgery to the time of death for any cause and will be censored at the date of last follow up visit for patients who are still alive or lost to follow up.

Analysis population: For OS, 12/51 patients were not evaluable due to either never having completed surgery, not receiving HIPEC, or having no evidence of cancer at time of surgery. As such, 39 patients were evaluable for OS. 2 patients died within 30 days of surgery and, as such, the full range of dates was 0 months to time of last follow up prior to study termination (i.e., 60 months)

Groups in this outcome

HIPEC + Mitomycin C

HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, were administered into the inflow line of the perfusion circuit once target temperature was reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, was administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period had elapsed, the perfusate was drained into the waste reservoir. The peritoneal cavity was rinsed/washed-out. HIPEC Mitomycin C

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
HIPEC + Mitomycin C39

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
HIPEC + Mitomycin C33.6Not reported060Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        60
        value
        33.6
denoms
  1. counts
    1. group Id
      OG000
      value
      39
    units
    Participants
description
Overall survival will be calculated from the time of surgery to the time of death for any cause and will be censored at the date of last follow up visit for patients who are still alive or lost to follow up.
dispersion Type
Full Range
groups
  1. description
    HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, were administered into the inflow line of the perfusion circuit once target temperature was reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, was administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period had elapsed, the perfusate was drained into the waste reservoir. The peritoneal cavity was rinsed/washed-out. HIPEC Mitomycin C
    id
    OG000
    title
    HIPEC + Mitomycin C
param Type
MEDIAN
population Description
For OS, 12/51 patients were not evaluable due to either never having completed surgery, not receiving HIPEC, or having no evidence of cancer at time of surgery. As such, 39 patients were evaluable for OS. 2 patients died within 30 days of surgery and, as such, the full range of dates was 0 months to time of last follow up prior to study termination (i.e., 60 months)
reporting Status
POSTED
time Frame
Up to 5 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice